ANTIVIRAL THERAPY

metrics 2024

Elevating knowledge in the fight against viruses.

Introduction

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Metrics 2024

SCIMAGO Journal Rank0.45
Journal Impact Factor1.30
Journal Impact Factor (5 years)1.50
H-Index93
Journal IF Without Self1.30
Eigen Factor0.00
Normal Eigen Factor0.20
Influence0.45
Immediacy Index0.60
Cited Half Life11.10
Citing Half Life6.60
JCI0.22
Total Documents2366
WOS Total Citations1736
SCIMAGO Total Citations22134
SCIMAGO SELF Citations1137
Scopus Journal Rank0.45
Cites / Document (2 Years)1.45
Cites / Document (3 Years)1.47
Cites / Document (4 Years)1.41

Metrics History

Rank 2024

Scopus

Pharmacology (medical) in Medicine
Rank #165/272
Percentile 39.34
Quartile Q3
Infectious Diseases in Medicine
Rank #211/344
Percentile 38.66
Quartile Q3
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #219/313
Percentile 30.03
Quartile Q3

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 112/132
Percentile 15.50
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 283/354
Percentile 20.20
Quartile Q4
VIROLOGY
Rank 37/41
Percentile 11.00
Quartile Q4

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 116/132
Percentile 12.12
Quartile Q4
PHARMACOLOGY & PHARMACY
Rank 309/354
Percentile 12.71
Quartile Q4
VIROLOGY
Rank 39/41
Percentile 4.88
Quartile Q4

Quartile History

Similar Journals

Advances in Virology

Advancing Knowledge, Transforming Virology
Publisher: HINDAWI LTDISSN: 1687-8639Frequency: 1 issue/year

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

FUNDAMENTAL & CLINICAL PHARMACOLOGY

Bridging research and practice in pharmacology and clinical medicine.
Publisher: WILEYISSN: 0767-3981Frequency: 6 issues/year

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Influenza and Other Respiratory Viruses

Exploring the frontiers of viral epidemiology.
Publisher: WILEYISSN: 1750-2640Frequency: 6 issues/year

Influenza and Other Respiratory Viruses, published by WILEY, serves as a prominent peer-reviewed platform for the dissemination of research contributing to the understanding and management of respiratory viral infections. With an impressive impact factor and established as an Open Access journal since 2014, it ensures maximum visibility and accessibility of pivotal research findings in the realm of Epidemiology, Infectious Diseases, Public Health, and Pulmonary and Respiratory Medicine. Registered under the ISSN 1750-2640 and E-ISSN 1750-2659, the journal boasts Q1 rankings in four critical categories as of 2023, underscoring its significance within the scientific community. Researchers, professionals, and students can benefit from the convergence of knowledge that this journal facilitates from 2007 to 2024, fostering advancements in understanding viral pathogens and innovative treatment strategies that are increasingly vital to public health efforts globally.

Journal of Virology

Transforming Insights into Virology and Health
Publisher: AMER SOC MICROBIOLOGYISSN: 0022-538XFrequency: 12 issues/year

Journal of Virology is a premier scholarly journal dedicated to advancing the field of virology, focusing on the molecular mechanisms of virus-host interactions, viral pathogenesis, and the latest therapeutic and vaccine developments. Published by the American Society for Microbiology, this esteemed journal has been a cornerstone for researchers since its inception in 1967, providing a platform for high-quality, peer-reviewed research. With a commendable impact factor indicative of its relevance and influence, the journal is categorized in the top quartile (Q1) for Virology, Microbiology, and Insect Science, reflecting its significance in these fields. Researchers can access a wealth of studies and findings that shape our understanding of viruses and their interactions with hosts, highlighting its role in both basic and applied sciences. Positioned in the United States, the Journal of Virology serves a global audience, ensuring that cutting-edge discoveries reach professionals, students, and academics alike. Join the conversation as we explore the complexities of virology and its implications for human health and disease.

JOURNAL DE MYCOLOGIE MEDICALE

Advancing Understanding of Fungal Infections
Publisher: MASSON EDITEURISSN: 1156-5233Frequency: 4 issues/year

JOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.

Infectious Diseases and Therapy

Exploring the frontiers of infectious disease management.
Publisher: SPRINGER LONDON LTDISSN: 2193-8229Frequency: 4 issues/year

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Journal of Clinical Virology Plus

Shaping the future of virology with cutting-edge findings.
Publisher: ELSEVIERISSN: 2667-0380Frequency: 4 issues/year

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

ANTI-CANCER DRUGS

Unveiling Breakthroughs in Cancer Therapeutics
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0959-4973Frequency: 10 issues/year

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

VIROLOGICA SINICA

Illuminating the Pathways of Infectious Disease Research
Publisher: KEAI PUBLISHING LTDISSN: 1674-0769Frequency: 6 issues/year

VIROLOGICA SINICA, published by KEAI PUBLISHING LTD, is a leading international journal dedicated to the field of virology. With an ISSN of 1674-0769 and E-ISSN of 1995-820X, this esteemed journal showcases cutting-edge research from 2006 to 2024, focusing on critical developments in Immunology, Infectious Diseases, Molecular Medicine, and Virology. As evidenced by its respectable positioning in the Q2 quartile of relevant categories and impressive Scopus rankings—such as Rank #20/80 in Virology—VIROLOGICA SINICA serves as an essential resource for researchers, professionals, and students aiming to deepen their understanding of viral pathogens and their impact on human health. While the journal does not currently offer open access, it remains an invaluable publication for those seeking to stay at the forefront of virology research. Its address is located at 16 Donghuangchenggen North St, Beijing, China, where it continues to foster academic excellence in the rapidly evolving landscape of virology.

JOURNAL OF CLINICAL VIROLOGY

Advancing the Frontiers of Viral Research
Publisher: ELSEVIERISSN: 1386-6532Frequency: 12 issues/year

Journal of Clinical Virology, published by Elsevier, stands at the forefront of virology research, focusing on the clinical implications of viral diseases. With an impressive impact factor representative of its Q1 categorization in both Infectious Diseases and Virology, this journal is essential for researchers and healthcare professionals aiming to keep pace with evolving knowledge and treatments in virology. Since its inception in 1998, it has provided a vital platform for the dissemination of significant breakthroughs, now continuing through to 2024. The journal boasts competitive Scopus ranks, placing it in the 95th percentile for Infectious Diseases and the 91st percentile for Virology. Scholars can benefit from its selective Open Access options, promoting widespread access to cutting-edge research. With an ever-increasing demand for innovative solutions to viral infections, Journal of Clinical Virology remains dedicated to fostering advancements in the field, making it a key resource for anyone invested in virology and infectious disease management.